SynlogicSTU:MIN 28 OCF Yield % is -41.75 as of Jun. 28, 2026. GuruFocus rates STU:MIN with a GF Score™ of 28/100 and a GF Value™ of €0.16. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Synlogic ranks worse than 81.16% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Synlogic OCF Yield % Related Terms
Synlogic OCF Yield % Historical Data
* Premium members only.
The historical data trend for Synlogic's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MIN vs CNSP, ELAB, GNPX: OCF Yield % Comparison
For the Biotechnology subindustry, Synlogic's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synlogic OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Synlogic's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Synlogic's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synlogic (STU:MIN) has a OCF Yield % of -41.75 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Synlogic and its competitors. According to the industry distribution chart, Synlogic ranks #1150 out of 1417 companies in the Biotechnology industry, placing it in the top 81.2%.
Is Synlogic's OCF Yield % too high?
Synlogic's current OCF Yield % is -41.75. Based on the distribution chart, Synlogic ranks #1150 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Synlogic has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Synlogic's OCF Yield % compare to CNSP and ELAB?
According to the Biotechnology industry distribution chart, Synlogic ranks #1150 out of 1417 companies for OCF Yield %. This places Synlogic in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Synlogic and its competitors. Synlogic's current OCF Yield % is -41.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synlogic stock overvalued right now?
Synlogic (STU:MIN) has a current OCF Yield % of -41.75. The stock's GF Value™ is €0.16, compared to a current price of €3.63 — trading 2168.8% above its estimated fair value. The current OCF Yield % is -41.75. Synlogic's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Synlogic (STU:MIN), the current OCF Yield % is -41.75 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synlogic (STU:MIN) Overvalued in 2026?
Based on GuruFocus' analysis, Synlogic stock appears to be overvalued.
The current stock price of €3.63 is trading 2168.8% above its estimated GF Value™ of €0.16.
Key valuation signals for STU:MIN:
OCF Yield %: -41.75
GF Value™: €0.16 vs. price of €3.63 (2168.8% above fair value)
No single metric tells the full story. See the STU:MIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. The pipeline drug candidates includes: labafenogene marselecobac (SYNB1934); SYNB1353 Classical Homocystinuria (HCU); SYNB8802 Enteric Hyperoxaluria; and SYNB2081 Gout. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one operating segment: Discovery and development of Synthetic Biotics.
28GF Score
Get the complete analysis for STU:MIN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MIN has been successfully added to your 
